Chronic hepatitis b associated without/with a delta agent in Kyrgyzstan (epidemiological situation, clinical features)

Objective. To compare epidemiological, clinical and laboratory characteristics of chronic hepatitis B (ChHB) associated with/without delta agent (ChHB+DV) study.Materials and methods. The Kyrgyzstan State Reporting Form No. 12 covering 2010–2017 period was examined. For this, 133 and 130 case histor...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: K. A. Nogoibaeva, S. T. Tobokalova, D. S. Bekenova, J. N Nazarbaeva
Formato: article
Lenguaje:RU
Publicado: Sankt-Peterburg : NIIÈM imeni Pastera 2019
Materias:
Acceso en línea:https://doaj.org/article/92f2d59d8613449eac742e78da7934f1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:92f2d59d8613449eac742e78da7934f1
record_format dspace
spelling oai:doaj.org-article:92f2d59d8613449eac742e78da7934f12021-11-22T07:09:53ZChronic hepatitis b associated without/with a delta agent in Kyrgyzstan (epidemiological situation, clinical features)2220-76192313-739810.15789/2220-7619-2019-3-4-577-582https://doaj.org/article/92f2d59d8613449eac742e78da7934f12019-11-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/784https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398Objective. To compare epidemiological, clinical and laboratory characteristics of chronic hepatitis B (ChHB) associated with/without delta agent (ChHB+DV) study.Materials and methods. The Kyrgyzstan State Reporting Form No. 12 covering 2010–2017 period was examined. For this, 133 and 130 case histories of ChHB and ChHB+DV patients, respectively, were analyzed. The data were statiastically processed by using Microsoft Office Excel software.Results and discussion. Over the 2010–2017 period, prevalence of the “HBV Carrier” (60.4 ) was higher by 20-fold than that one for ChHB [3.8 , 95% CI (2.4–4.0)] and CVHD [3.4 , 95% CI (2.2–3.4)], as the vast majority of patients were not thoroughly examined after detecting HBsAg, and the HBV Carrier was empirically diagnosed at the primary health care units. As a result, routine case definitions for such conditions were revised and an improved system of epidemiological surveillance of viral hepatitis was developed, according to the 2016 WHO recommendations approved by the Ministry of Health of the Kyrgyz Republic (Order No. 524, dated of July 20, 2018). Asthenia was observed in ~60% of patients in both groups, whereas arthralgia — in ~5–10% of patients, more often in those comorbid with ChHB+DV, and myalgia — in as low as ~3% of cases. Impaired central nervous system functions manifested as headache and restless sleep were evenly recorded in about 10–15% of patients, without significant difference between groups. In contrast, dominating dyspeptic manifestations such as poor appetite (72±3.9% vs. 20.6±3.5%, p < 0,05), nausea (23.8±3.7% vs. 7.3±2.3%, p < 0,05), vomiting (12.3±2.6% vs. 3.3±1.5%, p < 0,05) and flatulence (27±3.9% and 13±2.9%, p < 0,05) were revealed in ChHB+DV patients. Pain in the right hypochondrium was noted in 52–56% of patients, insignificantly differed between patient groups. Incidence of yellowness of the sclera and skin layers as well as skin itching were recorded by 2–3 and 8 times, respectively, more frequently in ChHB+DV patients. A more profound cytolysis and signs of altered bilirubin metabolism were also more common in HBV patients comorbid with the delta agent. Thus, a more severe ChHB+DV course requires that all patients with primary HBsAg detection were mandatorily examined for anti-HDV antibodies to ensure early diagnostics and timely organization of the secondary and tertiary preventive measures in the Kyrgyzstan.K. A. NogoibaevaS. T. TobokalovaD. S. BekenovaJ. N NazarbaevaSankt-Peterburg : NIIÈM imeni Pasteraarticlemorbiditycliniclaboratory parametersviral loadchronic hepatitis bchronic hepatitis b with delta agentkyrgyzstanInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 9, Iss 3-4, Pp 577-582 (2019)
institution DOAJ
collection DOAJ
language RU
topic morbidity
clinic
laboratory parameters
viral load
chronic hepatitis b
chronic hepatitis b with delta agent
kyrgyzstan
Infectious and parasitic diseases
RC109-216
spellingShingle morbidity
clinic
laboratory parameters
viral load
chronic hepatitis b
chronic hepatitis b with delta agent
kyrgyzstan
Infectious and parasitic diseases
RC109-216
K. A. Nogoibaeva
S. T. Tobokalova
D. S. Bekenova
J. N Nazarbaeva
Chronic hepatitis b associated without/with a delta agent in Kyrgyzstan (epidemiological situation, clinical features)
description Objective. To compare epidemiological, clinical and laboratory characteristics of chronic hepatitis B (ChHB) associated with/without delta agent (ChHB+DV) study.Materials and methods. The Kyrgyzstan State Reporting Form No. 12 covering 2010–2017 period was examined. For this, 133 and 130 case histories of ChHB and ChHB+DV patients, respectively, were analyzed. The data were statiastically processed by using Microsoft Office Excel software.Results and discussion. Over the 2010–2017 period, prevalence of the “HBV Carrier” (60.4 ) was higher by 20-fold than that one for ChHB [3.8 , 95% CI (2.4–4.0)] and CVHD [3.4 , 95% CI (2.2–3.4)], as the vast majority of patients were not thoroughly examined after detecting HBsAg, and the HBV Carrier was empirically diagnosed at the primary health care units. As a result, routine case definitions for such conditions were revised and an improved system of epidemiological surveillance of viral hepatitis was developed, according to the 2016 WHO recommendations approved by the Ministry of Health of the Kyrgyz Republic (Order No. 524, dated of July 20, 2018). Asthenia was observed in ~60% of patients in both groups, whereas arthralgia — in ~5–10% of patients, more often in those comorbid with ChHB+DV, and myalgia — in as low as ~3% of cases. Impaired central nervous system functions manifested as headache and restless sleep were evenly recorded in about 10–15% of patients, without significant difference between groups. In contrast, dominating dyspeptic manifestations such as poor appetite (72±3.9% vs. 20.6±3.5%, p < 0,05), nausea (23.8±3.7% vs. 7.3±2.3%, p < 0,05), vomiting (12.3±2.6% vs. 3.3±1.5%, p < 0,05) and flatulence (27±3.9% and 13±2.9%, p < 0,05) were revealed in ChHB+DV patients. Pain in the right hypochondrium was noted in 52–56% of patients, insignificantly differed between patient groups. Incidence of yellowness of the sclera and skin layers as well as skin itching were recorded by 2–3 and 8 times, respectively, more frequently in ChHB+DV patients. A more profound cytolysis and signs of altered bilirubin metabolism were also more common in HBV patients comorbid with the delta agent. Thus, a more severe ChHB+DV course requires that all patients with primary HBsAg detection were mandatorily examined for anti-HDV antibodies to ensure early diagnostics and timely organization of the secondary and tertiary preventive measures in the Kyrgyzstan.
format article
author K. A. Nogoibaeva
S. T. Tobokalova
D. S. Bekenova
J. N Nazarbaeva
author_facet K. A. Nogoibaeva
S. T. Tobokalova
D. S. Bekenova
J. N Nazarbaeva
author_sort K. A. Nogoibaeva
title Chronic hepatitis b associated without/with a delta agent in Kyrgyzstan (epidemiological situation, clinical features)
title_short Chronic hepatitis b associated without/with a delta agent in Kyrgyzstan (epidemiological situation, clinical features)
title_full Chronic hepatitis b associated without/with a delta agent in Kyrgyzstan (epidemiological situation, clinical features)
title_fullStr Chronic hepatitis b associated without/with a delta agent in Kyrgyzstan (epidemiological situation, clinical features)
title_full_unstemmed Chronic hepatitis b associated without/with a delta agent in Kyrgyzstan (epidemiological situation, clinical features)
title_sort chronic hepatitis b associated without/with a delta agent in kyrgyzstan (epidemiological situation, clinical features)
publisher Sankt-Peterburg : NIIÈM imeni Pastera
publishDate 2019
url https://doaj.org/article/92f2d59d8613449eac742e78da7934f1
work_keys_str_mv AT kanogoibaeva chronichepatitisbassociatedwithoutwithadeltaagentinkyrgyzstanepidemiologicalsituationclinicalfeatures
AT sttobokalova chronichepatitisbassociatedwithoutwithadeltaagentinkyrgyzstanepidemiologicalsituationclinicalfeatures
AT dsbekenova chronichepatitisbassociatedwithoutwithadeltaagentinkyrgyzstanepidemiologicalsituationclinicalfeatures
AT jnnazarbaeva chronichepatitisbassociatedwithoutwithadeltaagentinkyrgyzstanepidemiologicalsituationclinicalfeatures
_version_ 1718417930655367168